TABLE 2.
Prevalence of E. histolytica infection in ALA cases and close associate controlsa
| Group | No. infected/no. in group (% infected) at:
|
||||
|---|---|---|---|---|---|
| 0-6 mo | 9-18 mo | 21-27 mo | 30-36 mo | 0-36 mo | |
| ALA cases | 5/80 (6.3)*a | 8/80 (10)*a | 4/68 (5.9)*a | 2/64 (3.1) | 12/77 (15.6) |
| New infections | 6/8 | 1/4 | 0/2 | ||
| Controls | 9/737 (1.2)†a | 19/40 (2.6)†a | 5/725 (0.7) | 7/665 (1.0) | 25/703 (3.5) |
| New infections | 13/19 | 3/5 | 0/7 | ||
a
Includes only those subjects who had samples collected at baseline and during follow-up. *, P < 0.05 for prevalence of E. histolytica infection in ALA cases compared to controls during follow-up; †, P < 0.05 for prevalence of E. histolytica infection in controls 9 to 18 months compared to 21 to 27 and 30 to 36 months of follow-up.